SCHEMBL1774240

SCHEMBL1774240

COC(=O)c1ccc(C(=O)c2ccc(Cl)cc2CBr)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.49
RAB9A P51151 2/20 0.49
FLT1 P17948 1/20 0.47
FLT4 P35916 1/20 0.47
KDR P35968 1/20 0.47
ABL1 P00519 1/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
CYP1A2 P05177 1/20 0.45
CYP2C19 P33261 1/20 0.45
NLRP3 Q96P20 1/20 0.42
MAP2K4 P45985 1/20 0.42
SRD5A2 P31213 1/20 0.42
ALDH1A1 P00352 5/20 0.42
KDM4E B2RXH2 3/20 0.42
POLB P06746 2/20 0.42
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
CASP1 P29466 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1017404 0.85 ABL1 (0.58) MAPTRAB9AFLT1FLT4KDR
SCHEMBL1772591 0.81 MAPT (0.55) MAPTRAB9AFLT1FLT4KDR
SCHEMBL1772614 0.80 TSHR (0.50) MAPTRAB9AKMT2ACYP1A2CYP2C19
SCHEMBL30832832 0.77 KDM4E (0.57) MAPTKMT2AALDH1A1KDM4EGLA
SCHEMBL11601201 0.77 KDM4E (0.57) MAPTKMT2AALDH1A1KDM4EGLA
SCHEMBL11295587 0.77 KDM4E (0.62) MAPTRAB9AFLT1FLT4KDR
SCHEMBL942693 0.76 ABL1 (0.54) MAPTABL1MEN1KMT2AALDH1A1
SCHEMBL29752442 0.76 ABL1 (0.54) MAPTABL1MEN1KMT2AALDH1A1
SCHEMBL11289664 0.75 MEN1 (0.71) MAPTRAB9AMEN1KMT2AALDH1A1
SCHEMBL1773501 0.75 NPC1 (0.46) MAPTRAB9AMEN1KMT2AMAP2K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110112097-A1 Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof SANOFI-AVENTIS (FR) 2011-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112097-A1 Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof GIPR, PGC, DDC MAPT 4842/4885RAB9A 1148/4885FLT1 2509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.